Abstract P3-14-20: Phase 1 Dose-Escalation Study of the Investigational HER2/EGFR Inhibitor TAK-285 in Patients with Advanced Cancer

2010 ◽  
Author(s):  
P LoRusso ◽  
EG Chiorean ◽  
E Heath ◽  
A Weise ◽  
M Foley ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Egfr Inhibitor ◽  
Dose Escalation Study

Phase 1 dose escalation study of copanlisib (BAY 80-6946) in combination with gemcitabine or gemcitabine-cisplatin in advanced cancer patients.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 2610-2610 ◽  
Author(s):  
Richard D. Kim ◽  
Steven R. Alberts ◽  
Frank Gary Renshaw ◽  
Isabelle Genvresse ◽  
Stefanie Reif ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Advanced Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Advanced Cancer Patients ◽  
Dose Escalation Study

Phase 1 dose escalation study of rigosertib by 2-, 4-, or 8-hour infusion twice-weekly in patients with advanced cancer

2014 ◽  
Vol 51 (1) ◽  
pp. 40 ◽  
Author(s):  
D Raghunadharao ◽  
FE Wilhelm ◽  
M Acharya ◽  
SH Advani ◽  
SD Achrekar ◽  
...  
Keyword(s):  
Advanced Cancer ◽  
Dose Escalation ◽  
Phase 1 ◽  
Dose Escalation Study

scholarly journals Inhibition of Complement C3 in Geographic Atrophy with NGM621: Phase 1 Dose-Escalation Study Results

2021 ◽  
Author(s):  
Charles C. Wykoff ◽  
Vrinda Hershberger ◽  
David Eichenbaum ◽  
Erin Henry ◽  
Husam S. Younis ◽  
...  
Keyword(s):  
Dose Escalation ◽  
Phase 1 ◽  
Geographic Atrophy ◽  
Complement C3 ◽  
Dose Escalation Study ◽  
Study Results
Sign in / Sign up

Export Citation Format

Share Document